Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 306 articles:
HTML format



Single Articles


    June 2024
  1. CLAUDIANI S, Chee L, Fernando F, Brown L, et al
    Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations.
    Am J Hematol. 2024;99:1172-1174.
    PubMed     Abstract available


    May 2024
  2. DEVILLIER R, Galimard JE, Blaise D, Raiola AM, et al
    Peripheral blood stem cell versus bone marrow graft for patients >/=60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of
    Am J Hematol. 2024 May 23. doi: 10.1002/ajh.27343.
    PubMed     Abstract available


  3. KOCKEROLS C, Valk PJM, Dulucq S, Nicolini FE, et al
    BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.
    Am J Hematol. 2024 May 20. doi: 10.1002/ajh.27359.
    PubMed    


  4. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
    Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
    Am J Hematol. 2024 May 17. doi: 10.1002/ajh.27367.
    PubMed    


  5. BEWERSDORF JP, Shimony S, Shallis RM, Liu Y, et al
    Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
    Am J Hematol. 2024 May 15. doi: 10.1002/ajh.27366.
    PubMed    


  6. RANAWEERA ARACHCHIGE T, Mendiburu C, Martin A, Fleury C, et al
    Clinical and biological characterization of involvement of nasal-associated lymphoid tissues in chronic lymphocytic leukemia.
    Am J Hematol. 2024 May 10. doi: 10.1002/ajh.27357.
    PubMed    


  7. SHOMALI W, Gotlib J
    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2024;99:946-968.
    PubMed     Abstract available


  8. CIUREA SO, Kongtim P, Srour S, Chen J, et al
    Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.
    Am J Hematol. 2024;99:890-899.
    PubMed     Abstract available


  9. ORVAIN C, Ali N, Othus M, Rodriguez-Arboli E, et al
    Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
    Am J Hematol. 2024;99:862-870.
    PubMed     Abstract available


  10. NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al
    Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.
    Am J Hematol. 2024;99:806-815.
    PubMed     Abstract available


    April 2024
  11. YE Y, Labopin M, Gerard S, Yakoub-Agha I, et al
    Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the Europea
    Am J Hematol. 2024 Apr 24. doi: 10.1002/ajh.27342.
    PubMed     Abstract available


  12. ZHOU Z, Zhuo N, Zhou Y, Sun C, et al
    Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients.
    Am J Hematol. 2024 Apr 23. doi: 10.1002/ajh.27340.
    PubMed    


  13. SZUBER N, Orazi A, Tefferi A
    Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
    Am J Hematol. 2024 Apr 21. doi: 10.1002/ajh.27321.
    PubMed     Abstract available


  14. SHORT NJ, Jabbour E, Nasr LF, Jain N, et al
    Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
    Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329.
    PubMed    


  15. CRAMER P, von Tresckow J, Fink AM, Robrecht S, et al
    Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
    Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304.
    PubMed    


  16. MUSICK JO, Williams EK, Fibben KS, Zhang DY, et al
    Redefining hyperviscosity in acute leukemia: Potential implications for red cell transfusions in the microvasculature.
    Am J Hematol. 2024 Apr 4. doi: 10.1002/ajh.27308.
    PubMed     Abstract available


  17. KHAN AA, James D, Andresen V, Atkey J, et al
    Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
    Am J Hematol. 2024 Apr 3. doi: 10.1002/ajh.27301.
    PubMed    


  18. LITZOW MR
    Building a better blinatumomab.
    Am J Hematol. 2024;99:512-514.
    PubMed    


  19. HU S, Jabbour EJ, Hu CY, Tang G, et al
    Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive B-ALL and pose a diagnostic challenge.
    Am J Hematol. 2024;99:721-726.
    PubMed    


    March 2024
  20. HADDAD FG, Sasaki K, Issa GC, Jabbour E, et al
    The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia.
    Am J Hematol. 2024 Mar 28. doi: 10.1002/ajh.27307.
    PubMed    


  21. TANG H, Jia W, Jia S, Dong R, et al
    A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
    Am J Hematol. 2024 Mar 14. doi: 10.1002/ajh.27289.
    PubMed    


  22. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
    Am J Hematol. 2024 Mar 7. doi: 10.1002/ajh.27271.
    PubMed     Abstract available


  23. TROUSSARD X, Maitre E, Paillassa J
    Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
    Am J Hematol. 2024 Mar 5. doi: 10.1002/ajh.27240.
    PubMed     Abstract available


    February 2024
  24. MIRVIS E, Sairam S, Vainieri E, Tona F, et al
    Pituitary apoplexy in acute promyelocytic leukemia.
    Am J Hematol. 2024 Feb 29. doi: 10.1002/ajh.27277.
    PubMed    


  25. JIANG M, Wang X, Yu M, Jiang S, et al
    Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia.
    Am J Hematol. 2024 Feb 27. doi: 10.1002/ajh.27272.
    PubMed     Abstract available


  26. SANDBERG Y, Budel LM, Bain BJ
    Neutrophilic leukemoid reaction or chronic neutrophilic leukemia-not always so simple.
    Am J Hematol. 2024 Feb 23. doi: 10.1002/ajh.27268.
    PubMed    


  27. GANGAT N, Tefferi A
    Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
    Am J Hematol. 2024 Feb 20. doi: 10.1002/ajh.27256.
    PubMed     Abstract available


  28. BATALLER A, DiNardo CD, Bazinet A, Daver NG, et al
    Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
    Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27236.
    PubMed     Abstract available


  29. KITTAI AS, Hang Y, Bhat SA, Clark A, et al
    Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
    Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27241.
    PubMed     Abstract available


  30. PRATZ KW, Jonas BA, Pullarkat V, Thirman MJ, et al
    Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27246.
    PubMed     Abstract available


  31. AUTORE F, Visentin A, Deodato M, Vitale C, et al
    Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27247.
    PubMed    


  32. ABAZA Y, Winer ES, Murthy GSG, Shallis RM, et al
    Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27231.
    PubMed     Abstract available


  33. CHEN X, Yuan L, Zhang Y, Wang F, et al
    Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
    Am J Hematol. 2024 Feb 6. doi: 10.1002/ajh.27249.
    PubMed     Abstract available


  34. JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al
    Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227.
    PubMed     Abstract available


  35. HORNAK T, Mayer J, Cicatkova P, Semerad L, et al
    De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27229.
    PubMed     Abstract available


  36. BENESOVA A, De Santis S, Polivkova V, Pecherkova P, et al
    Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232.
    PubMed    


  37. KURITA N, Imahashi N, Chiba S, Tanaka M, et al
    Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study.
    Am J Hematol. 2024;99:236-244.
    PubMed     Abstract available


  38. GURNARI C, Pascale MR, Vitale A, Diral E, et al
    Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
    Am J Hematol. 2024;99:254-262.
    PubMed     Abstract available


  39. DINARDO CD
    Toward an improved understanding of hypomethylating agent and venetoclax therapies.
    Am J Hematol. 2024;99:152-154.
    PubMed    


  40. BRUNNER AM, Esteve J, Porkka K, Knapper S, et al
    Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
    Am J Hematol. 2024;99:E32-E36.
    PubMed     Abstract available


    January 2024
  41. CAMPANELLA A, Capasso A, Heltai S, Taccetti C, et al
    Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
    Am J Hematol. 2024 Jan 24. doi: 10.1002/ajh.27218.
    PubMed     Abstract available


  42. IM A, Quann K, Agha M, Raptis A, et al
    Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
    Am J Hematol. 2024 Jan 22. doi: 10.1002/ajh.27212.
    PubMed     Abstract available


  43. VARDELL VA, Ermann DA, Fitzgerald L, Shah H, et al
    T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments.
    Am J Hematol. 2024 Jan 19. doi: 10.1002/ajh.27205.
    PubMed     Abstract available



  44. Correction to "Analysis of 60 Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Treated with CD7-targeted Chimeric Antigen Receptor-T Cell Therapy".
    Am J Hematol. 2024 Jan 15. doi: 10.1002/ajh.27217.
    PubMed    


  45. BARON F, Efficace F, Cannella L, Stevens-Kroef M, et al
    Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
    Am J Hematol. 2024 Jan 4. doi: 10.1002/ajh.27196.
    PubMed     Abstract available


  46. MOUKALLED N, Labopin M, Versluis J, Socie G, et al
    Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Le
    Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27187.
    PubMed     Abstract available


  47. PELLAND-MARCOTTE MC, Kulkarni K, Tran TH, Stammers D, et al
    Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C.
    Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27171.
    PubMed     Abstract available


  48. SPONSEILER I, Bandian AM, Pusic P, Lion T, et al
    Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias.
    Am J Hematol. 2024;99:E9-E11.
    PubMed    


  49. TEFFERI A, Abdelmagid M, Al-Kali A, Patnaik M, et al
    Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
    Am J Hematol. 2024;99:21-27.
    PubMed     Abstract available


    December 2023
  50. MOLICA S, Shanafelt TD, Allsup D, Giannarelli D, et al
    Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population.
    Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27182.
    PubMed     Abstract available


  51. KARRAR O, Abdelmagid M, Rana M, Iftikhar M, et al
    Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
    Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27180.
    PubMed     Abstract available


  52. GANGAT N, Karrar O, Iftikhar M, McCullough K, et al
    Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
    Am J Hematol. 2023 Dec 10. doi: 10.1002/ajh.27138.
    PubMed     Abstract available


  53. JOSHI SK, Pittsenbarger J, Kennedy VE, Peretz CAC, et al
    The FLT3(N701K) mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
    Am J Hematol. 2023;98:E364-E368.
    PubMed    


  54. OLIVA-ARIZA G, Fuentes-Herrero B, Lecrevisse Q, Carbonell C, et al
    Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis.
    Am J Hematol. 2023;98:1909-1922.
    PubMed     Abstract available


    November 2023
  55. VALENT P
    Clinical impact of cytomorphology in mast cell leukemia.
    Am J Hematol. 2023 Nov 6. doi: 10.1002/ajh.27146.
    PubMed    


    October 2023
  56. GHERGUS D, Martin M, Knapp AM, Delmotte F, et al
    Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?
    Am J Hematol. 2023 Oct 19. doi: 10.1002/ajh.27137.
    PubMed     Abstract available


  57. SALIBA RM, Kanakry CG, Gadalla S, Kebriaei P, et al
    Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age.
    Am J Hematol. 2023 Oct 18. doi: 10.1002/ajh.27126.
    PubMed     Abstract available


  58. KITTAI AS, Skarbnik A, Miranda M, Yong ASM, et al
    A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.
    Am J Hematol. 2023 Oct 9. doi: 10.1002/ajh.27110.
    PubMed    


  59. ZHANG L, Yang X, Ge X, Li B, et al
    CMSS1::FLT1 rearrangement leads to ligand-independent activation of FLT1 signaling in acute myeloid leukemia.
    Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27108.
    PubMed    


  60. SUNG MT, Chen LH, Chiang YW, Jhuang JY, et al
    Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor-derived myelodysplastic syndrome using single-cell multi-omics analysis.
    Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27121.
    PubMed    


  61. HAZARIKA B, Bain BJ
    Pseudo-Chediak-Higashi anomaly in acute myeloid leukemia.
    Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27114.
    PubMed    


  62. HIRABAYASHI S, Kondo T, Nishiwaki S, Mizuta S, et al
    Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph(+) ALL: A retrospective nationwide study.
    Am J Hematol. 2023;98:1606-1618.
    PubMed     Abstract available


  63. CALABRESI L, Carretta C, Romagnoli S, Rotunno G, et al
    Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
    Am J Hematol. 2023;98:1520-1531.
    PubMed     Abstract available



  64. Abstracts from the 2023 Lymphoma, Leukemia and Myeloma Congress October 18-21, 2023.
    Am J Hematol. 2023;98 Suppl 5:S3-S57.
    PubMed    


    September 2023
  65. VISENTIN A, Chatzikonstantinou T, Scarfo L, Kapetanakis A, et al
    The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
    Am J Hematol. 2023 Sep 29. doi: 10.1002/ajh.27093.
    PubMed     Abstract available


  66. HADDAD FG, Short NJ
    Treatment discontinuation in chronic myeloid leukemia: When, how, and why?
    Am J Hematol. 2023 Sep 27. doi: 10.1002/ajh.27100.
    PubMed    


  67. ZHANG X, Yang J, Li J, Qiu L, et al
    Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
    Am J Hematol. 2023 Sep 23. doi: 10.1002/ajh.27094.
    PubMed     Abstract available


  68. TEFFERI A, Pardanani A, Al-Kali A, Alkhateeb H, et al
    Mast cell cytomorphology and treatment outcome in mast cell leukemia.
    Am J Hematol. 2023 Sep 21. doi: 10.1002/ajh.27105.
    PubMed    


  69. ANIL J, Alnemri A, Lytle A, Lockhart B, et al
    Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy in B-acute lymphoblastic leukemia.
    Am J Hematol. 2023 Sep 18. doi: 10.1002/ajh.27098.
    PubMed     Abstract available


  70. VON ASMUTH EGJ, Lankester AC, Putter H
    Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias?
    Am J Hematol. 2023 Sep 15. doi: 10.1002/ajh.27083.
    PubMed    


  71. PATEL PC, Ball S, Jain AG, Wang C, et al
    Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
    Am J Hematol. 2023 Sep 13. doi: 10.1002/ajh.27092.
    PubMed     Abstract available


  72. PARDANANI A, Tefferi A, Al-Kali A, Patnaik M, et al
    Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
    Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27089.
    PubMed     Abstract available


  73. NATH K, Lee J, Elko TA, Levy L, et al
    Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
    Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27084.
    PubMed     Abstract available


  74. FANG H, Medeiros LJ, Wang W
    Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?
    Am J Hematol. 2023 Sep 8. doi: 10.1002/ajh.27085.
    PubMed    


  75. RAVANDI F, Cloos J, Buccisano F, Dillon R, et al
    Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
    Am J Hematol. 2023 Sep 6. doi: 10.1002/ajh.27087.
    PubMed     Abstract available


  76. ZHOU JY, Wang S, Yuan HL, Xu YJ, et al
    Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML.
    Am J Hematol. 2023;98:1394-1406.
    PubMed     Abstract available


  77. TEFFERI A, Barbui T
    Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2023;98:1465-1487.
    PubMed     Abstract available


    August 2023
  78. ZAMBROTTA GPM, Nicolini FE, Assouline S, Busque L, et al
    Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
    Am J Hematol. 2023 Aug 30. doi: 10.1002/ajh.27073.
    PubMed     Abstract available


  79. KADIA TM, Ravandi F, Molica M, Bataller A, et al
    Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
    Am J Hematol. 2023 Aug 27. doi: 10.1002/ajh.27054.
    PubMed     Abstract available


  80. KOSYDAR SR, Parikh SA, Lester SC, Rabe KG, et al
    Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment.
    Am J Hematol. 2023 Aug 24. doi: 10.1002/ajh.27060.
    PubMed    


  81. GARCIA-MANERO G
    Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2023;98:1307-1325.
    PubMed     Abstract available


  82. WANG SA, Orazi A, Gotlib J, Reiter A, et al
    The international consensus classification of eosinophilic disorders and systemic mastocytosis.
    Am J Hematol. 2023;98:1286-1306.
    PubMed     Abstract available


  83. ZINI G, Bennett JM
    ICC-2022 versus WHO-2022 classification systems for acute leukemias and myeloid neoplasms: The perspective from two classical morphologists.
    Am J Hematol. 2023;98:E209-E211.
    PubMed    


  84. SHORT NJ, Jabbour E, Macaron W, Ravandi F, et al
    Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
    Am J Hematol. 2023;98:1196-1203.
    PubMed     Abstract available


  85. JELLOUL FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, et al
    DDX41 mutations in patients with non-myeloid hematologic neoplasms.
    Am J Hematol. 2023;98:E193-E196.
    PubMed    


    July 2023
  86. HADDAD FG, Sasaki K, Bidikian A, Issa GC, et al
    Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
    Am J Hematol. 2023 Jul 23. doi: 10.1002/ajh.27037.
    PubMed     Abstract available


  87. BRADY MT, Laniewski N, Strawderman M, Chu CC, et al
    Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.
    Am J Hematol. 2023 Jul 23. doi: 10.1002/ajh.27038.
    PubMed    


  88. ZUNA J, Hovorkova L, Krotka J, Winkowska L, et al
    Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
    Am J Hematol. 2023 Jul 14. doi: 10.1002/ajh.27022.
    PubMed    


  89. LOSCOCCO GG, Ascani S, Mannelli F, Zanelli M, et al
    Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
    Am J Hematol. 2023 Jul 12. doi: 10.1002/ajh.27026.
    PubMed    


  90. PARDANANI A
    Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
    Am J Hematol. 2023;98:1097-1116.
    PubMed     Abstract available


  91. FALINI B, Martelli MP, Brunetti L, Gjertsen BT, et al
    The NPM1 mutant defines AML irrespective of blast count.
    Am J Hematol. 2023;98:E187-E189.
    PubMed    


    June 2023
  92. VISENTIN A, Mauro FR, Scarfo L, Gentile M, et al
    Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
    Am J Hematol. 2023 Jun 29. doi: 10.1002/ajh.27009.
    PubMed    


  93. NAKA R, Kondo T, Nishikubo M, Muranushi H, et al
    Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
    Am J Hematol. 2023 Jun 28. doi: 10.1002/ajh.27012.
    PubMed    


  94. KANTARJIAN HM, Tefferi A
    Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress.
    Am J Hematol. 2023 Jun 26. doi: 10.1002/ajh.27007.
    PubMed    


  95. HORST HA, Zugmaier G, Martinelli G, Mergen N, et al
    CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis.
    Am J Hematol. 2023 Jun 22. doi: 10.1002/ajh.26988.
    PubMed    


  96. BAZINET A, Kantarjian H, Arani N, Popat U, et al
    Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
    Am J Hematol. 2023 Jun 19. doi: 10.1002/ajh.26997.
    PubMed     Abstract available


  97. MATTHEWS AH, Perl AE, Luger SM, Gill SI, et al
    Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
    Am J Hematol. 2023 Jun 19. doi: 10.1002/ajh.26991.
    PubMed     Abstract available


  98. FALINI B
    NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
    Am J Hematol. 2023 Jun 15. doi: 10.1002/ajh.26989.
    PubMed     Abstract available


  99. SALIBA AN, Foa R
    Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing.
    Am J Hematol. 2023 Jun 14. doi: 10.1002/ajh.26993.
    PubMed    


  100. JADI O, Tang H, Olsen K, Vensko S, et al
    Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation.
    Am J Hematol. 2023;98:940-950.
    PubMed     Abstract available


  101. TANG Y, Zhang Z, Liu S, Yao Y, et al
    Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation.
    Am J Hematol. 2023;98:881-889.
    PubMed     Abstract available


  102. FENU EM, Margolskee E, Pillai V
    Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy.
    Am J Hematol. 2023 Jun 1. doi: 10.1002/ajh.26983.
    PubMed    


    May 2023
  103. GIRARD S, Lours C
    Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
    Am J Hematol. 2023 May 25. doi: 10.1002/ajh.26969.
    PubMed    


  104. ROTBAIN EC, Allmer C, Rostgaard K, Andersen MA, et al
    Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia.
    Am J Hematol. 2023 May 22. doi: 10.1002/ajh.26964.
    PubMed     Abstract available


  105. ISHIDA H, Shimada H, Tanizawa A, Shimazu Y, et al
    Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era.
    Am J Hematol. 2023 May 12. doi: 10.1002/ajh.26959.
    PubMed     Abstract available


  106. DAVER NG, Iqbal S, Huang J, Renard C, et al
    Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.
    Am J Hematol. 2023 May 4. doi: 10.1002/ajh.26941.
    PubMed     Abstract available


  107. YANG S, Zhang X, Gale RP, Du X, et al
    Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
    Am J Hematol. 2023 May 2. doi: 10.1002/ajh.26943.
    PubMed    


  108. IVANOV D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, et al
    Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
    Am J Hematol. 2023;98:770-783.
    PubMed     Abstract available


  109. HUNTINGTON SF, Schuster SJ, Ding W, Koehler AB, et al
    DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
    Am J Hematol. 2023;98:739-749.
    PubMed     Abstract available


  110. MARCOUX C, Marin D, Ramdial J, AlAtrash G, et al
    Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS.
    Am J Hematol. 2023;98:712-719.
    PubMed     Abstract available


    April 2023
  111. FAN BE, Chen DTY, Ponnudurai K, Abdul Latiff STB, et al
    Artificial intelligence generated leukemia cell images.
    Am J Hematol. 2023 Apr 29. doi: 10.1002/ajh.26942.
    PubMed    


  112. VARDELL VA, Ermann DA, Fitzgerald LA, Shah HR, et al
    Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia.
    Am J Hematol. 2023 Apr 20. doi: 10.1002/ajh.26937.
    PubMed     Abstract available


  113. MORABITO F, Tripepi G, Mauro FR, Laurenti L, et al
    The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
    Am J Hematol. 2023 Apr 17. doi: 10.1002/ajh.26927.
    PubMed    


  114. FALINI B, Martelli MP, Brunetti L
    Mutant NPM1: Nuclear export and the mechanism of leukemogenesis.
    Am J Hematol. 2023;98:550-552.
    PubMed    


  115. HAMPEL PJ, Parikh SA
    BTKi bonanza in CLL/SLL: Sorting out the differences.
    Am J Hematol. 2023;98:556-559.
    PubMed    


  116. TEFFERI A, Bacigalup A
    Blast phase myeloproliferative neoplasm: Transplant to the rescue.
    Am J Hematol. 2023;98:553-555.
    PubMed    


  117. ORTI G, Gras L, Zinger N, Finazzi MC, et al
    Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantat
    Am J Hematol. 2023;98:628-638.
    PubMed     Abstract available


    March 2023
  118. ROSE A, Zhang L, Jain AG, Poovathukaran Babu A, et al
    Delineation of Clinical Course, Outcomes, and Prognostic Factors in Patients with T-cell Prolymphocytic Leukemia.
    Am J Hematol. 2023 Mar 25. doi: 10.1002/ajh.26918.
    PubMed     Abstract available


  119. BACHELOT A, Bouvier A, Riou J, Thepot S, et al
    Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: assessment of different risk scores.
    Am J Hematol. 2023 Mar 25. doi: 10.1002/ajh.26917.
    PubMed     Abstract available



  120. Corrigendum to "Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia".
    Am J Hematol. 2023 Mar 24. doi: 10.1002/ajh.26894.
    PubMed    


  121. GIPE N, Leung N, Lasho T, Mangaonkar A, et al
    Spectrum of renal pathological findings in patients with chronic myelomonocytic leukemia and kidney injury.
    Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26902.
    PubMed    


  122. ALDOSS I, Afkhami M, Yang D, Gu Z, et al
    High Response Rates and Transition to Transplant after Novel Targeted and Cellular Therapies in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia with Philadelphia-Like Fusions.
    Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26908.
    PubMed     Abstract available


  123. QIU KY, Wang JY, Huang LB, Li CG, et al
    Vincristine and Dexamethasone Pulses in Addition to Maintenance Therapy Among Pediatric Acute Lymphoblastic Leukemia(GD-ALL-2008): an Open-label, Multicentre, Randomized, Phase III Clinical Trial.
    Am J Hematol. 2023 Mar 6. doi: 10.1002/ajh.26910.
    PubMed     Abstract available


  124. DESIKAN SP, Senapati J, Jabbour E, Abuasab T, et al
    Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia.
    Am J Hematol. 2023 Mar 6. doi: 10.1002/ajh.26907.
    PubMed    


  125. KATODRITOU E, Kastritis E, Dalampira D, Delimpasi S, et al
    Improved Survival of Patients with Primary Plasma Cell Leukemia with VRd or Daratumumab-based Quadruplets: A Multicenter Study by the Greek Myeloma Study Group.
    Am J Hematol. 2023 Mar 4. doi: 10.1002/ajh.26891.
    PubMed     Abstract available


  126. LO MY, Tsai XC, Lin CC, Tien FM, et al
    Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
    Am J Hematol. 2023 Mar 2. doi: 10.1002/ajh.26892.
    PubMed     Abstract available


  127. YANG YT, Yao CY, Chiu PJ, Kao CJ, et al
    Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia.
    Am J Hematol. 2023 Mar 1. doi: 10.1002/ajh.26893.
    PubMed     Abstract available


    February 2023
  128. EPPERLA N, Zhao Q, Anghelina M, Neal J, et al
    Impact of sex on outcomes in patients with Hairy cell leukemia. An HCL Patient Data Registry analysis.
    Am J Hematol. 2023 Feb 20. doi: 10.1002/ajh.26881.
    PubMed    


  129. BADAT M, Sivaguru G, Bain BJ
    Ophthalmic presentation of chronic myeloid leukemia in two adolescents.
    Am J Hematol. 2023 Feb 16. doi: 10.1002/ajh.26884.
    PubMed    


  130. LEE BJ, Griffin SP, Doh J, Kongtim P, et al
    Timing of Intrathecal Chemotherapy and Blinatumomab Impacts Neurotoxicity in Acute Lymphoblastic Leukemia.
    Am J Hematol. 2023 Feb 16. doi: 10.1002/ajh.26880.
    PubMed    


  131. MEJIA SALDARRIAGA M, Alhomoud M, Roboz G, Allan JN, et al
    Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia.
    Am J Hematol. 2023 Feb 13. doi: 10.1002/ajh.26878.
    PubMed    


  132. ANTHERIEU G, Donzel M, Balme B, Traverse-Glehen A, et al
    Chronic myelomonocytic leukemia transdifferenciation landscape: from histiocytosis to blastic plasmacytoid dendritic cell neoplasm.
    Am J Hematol. 2023 Feb 13. doi: 10.1002/ajh.26876.
    PubMed    


  133. ZEIDAN AM, Borate U, Pollyea DA, Brunner AM, et al
    A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
    Am J Hematol. 2023;98:272-281.
    PubMed     Abstract available


  134. HERGOTT CB, Dal Cin P, Hornick JL, Winer ES, et al
    Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion.
    Am J Hematol. 2023;98:365-367.
    PubMed    


    January 2023
  135. WALIA A, Prasad V
    Is it time to reconsider molecular response milestones in chronic myeloid leukemia?
    Am J Hematol. 2023 Jan 28. doi: 10.1002/ajh.26867.
    PubMed    


  136. KIM MS, Prasad V
    Front-line chronic lymphocytic leukemia: The role of chemoimmunotherapy.
    Am J Hematol. 2023 Jan 26. doi: 10.1002/ajh.26864.
    PubMed    


  137. ALDOSS I, Shah BD, Park JH, Muffly L, et al
    Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2023 Jan 24. doi: 10.1002/ajh.26853.
    PubMed     Abstract available


  138. XU W, Zhou K, Wang T, Yang S, et al
    Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
    Am J Hematol. 2023 Jan 22. doi: 10.1002/ajh.26826.
    PubMed     Abstract available


  139. JABBOUR E, Sasaki K, Haddad FG, Issa GC, et al
    The Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line BCR::ABL1 Tyrosine Kinase Inhibitors.
    Am J Hematol. 2023 Jan 22. doi: 10.1002/ajh.26852.
    PubMed     Abstract available


  140. WEI AH, Dohner H, Sayar H, Ravandi F, et al
    Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
    Am J Hematol. 2023 Jan 19. doi: 10.1002/ajh.26847.
    PubMed    


  141. CANDONI A, Lazzarotto D, Papayannidis C, Piccini M, et al
    PROSPECTIVE MULTICENTER STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME OF 230 UNFIT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING FIRST-LINE THERAPY WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX.
    Am J Hematol. 2023 Jan 18. doi: 10.1002/ajh.26846.
    PubMed    


  142. GIEBEL S, Labopin M, Schroeder T, Swoboda R, et al
    Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Pa
    Am J Hematol. 2023 Jan 10. doi: 10.1002/ajh.26825.
    PubMed     Abstract available


  143. AL-KALI A, Tibes R, Atherton P, Palmer J, et al
    A Phase II Study of Combination Daunorubicin, Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia with KIT Expression.
    Am J Hematol. 2023 Jan 9. doi: 10.1002/ajh.26831.
    PubMed     Abstract available


  144. BIDIKIAN A, Jabbour E, Issa GC, Short NJ, et al
    Chronic Myeloid Leukemia Without Major Molecular Response After 2 Years of Treatment with Tyrosine Kinase Inhibitor.
    Am J Hematol. 2023 Jan 6. doi: 10.1002/ajh.26836.
    PubMed     Abstract available


  145. GURU MURTHY GS, Logan BR, Bo-Subait S, Beitinjaneh A, et al
    Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
    Am J Hematol. 2023 Jan 6. doi: 10.1002/ajh.26834.
    PubMed     Abstract available


  146. FALINI B, Martelli MP
    Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.
    Am J Hematol. 2023 Jan 5. doi: 10.1002/ajh.26812.
    PubMed     Abstract available


  147. PATNAIK MM, Tefferi A
    Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2023 Jan 4. doi: 10.1002/ajh.26828.
    PubMed     Abstract available


  148. KANTARJIAN H, Short NJ, Jain N, Sasaki K, et al
    Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
    Am J Hematol. 2023 Jan 4. doi: 10.1002/ajh.26816.
    PubMed     Abstract available


  149. MARTINO G, Quintini M, Martelli MP, Ascani S, et al
    Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia - aCML).
    Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26817.
    PubMed    


  150. SHIMONY S, Stahl M, Stone RM
    Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26822.
    PubMed     Abstract available


  151. HAZARIKA B, Bain BJ
    Granular B lymphoblastic leukemia.
    Am J Hematol. 2023;98:210-211.
    PubMed    


  152. THIELE J, Kvasnicka HM, Orazi A, Gianelli U, et al
    The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
    Am J Hematol. 2023;98:166-179.
    PubMed     Abstract available


  153. LEE WH, Lin CC, Tsai CH, Tien FM, et al
    Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26799.
    PubMed     Abstract available


  154. GRAF I, Greiner G, Marculescu R, Gleixner KV, et al
    N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26805.
    PubMed     Abstract available


  155. LIU H, Huang F, Zhang Y, Wu M, et al
    Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26800.
    PubMed     Abstract available


    December 2022
  156. ARBER DA, Hasserjian RP, Orazi A
    Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia.
    Am J Hematol. 2022 Dec 24. doi: 10.1002/ajh.26820.
    PubMed    


  157. SENAPATI J, Abuasab T, Haddad FG, Ravandi F, et al
    Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
    Am J Hematol. 2022 Dec 24. doi: 10.1002/ajh.26811.
    PubMed    


  158. SALIBA AN, Foa R
    The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: giant strides and ongoing challenges.
    Am J Hematol. 2022 Dec 20. doi: 10.1002/ajh.26813.
    PubMed    


  159. KWON A, Fuda F, Gagan J, John S, et al
    Rare circulating lymphoblasts with striking eosinophilia: A rare case of B lymphoblastic leukemia with PAX5::ZCCHC7.
    Am J Hematol. 2022 Dec 12. doi: 10.1002/ajh.26795.
    PubMed    


  160. PASVOLSKY O, Saliba RM, Ledesma C, Popat UR, et al
    Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission.
    Am J Hematol. 2022 Dec 11. doi: 10.1002/ajh.26789.
    PubMed    


    November 2022
  161. RADICH J
    Allogeneic transplantation for chronic myeloid leukemia: I'm not dead yet!
    Am J Hematol. 2022 Nov 24. doi: 10.1002/ajh.26790.
    PubMed    


  162. WIECZOREK M, Labopin M, Castagna L, Brissot E, et al
    Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
    Am J Hematol. 2022 Nov 18. doi: 10.1002/ajh.26782.
    PubMed    


  163. LEVI S, Bronstein Y, Goldschmidt N, Morabito F, et al
    Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
    Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26779.
    PubMed    


  164. WOYACH JA
    Management of relapsed/refractory Chronic Lymphocytic Leukemia.
    Am J Hematol. 2022;97 Suppl 2:S11-S18.
    PubMed     Abstract available


  165. ARONSON JH, Skanland SS, Roeker LE, Thompson MC, et al
    Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).
    Am J Hematol. 2022;97 Suppl 2:S19-S25.
    PubMed     Abstract available


  166. KUTSCH N, Fink AM, Fischer K
    Management of front line chronic lymphocytic leukemia.
    Am J Hematol. 2022;97 Suppl 2:S3-S10.
    PubMed     Abstract available


  167. CHIUSOLO P, Marchetti C, Rossi M, Minnella G, et al
    A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer.
    Am J Hematol. 2022;97:E400-E403.
    PubMed    


  168. MCVINNIE K, Innes A, Nadal-Melsio E, Atta M, et al
    A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.
    Am J Hematol. 2022;97:1491-1494.
    PubMed    


    October 2022
  169. ALDULESCU M, Leuer K, Jennings LJ, Yap KL, et al
    Lineage switch from acute myeloid leukemia to B-lymphoblastic lymphoma with acquired PIK3R1 loss-of-function mutation.
    Am J Hematol. 2022 Oct 26. doi: 10.1002/ajh.26770.
    PubMed    


  170. CHALANDON Y, Sbianchi G, Gras L, Koster L, et al
    Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
    Am J Hematol. 2022 Oct 20. doi: 10.1002/ajh.26764.
    PubMed     Abstract available


  171. STAHL M, Derkach A, Farnoud N, Bewersdorf JP, et al
    Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
    Am J Hematol. 2022 Oct 17. doi: 10.1002/ajh.26757.
    PubMed     Abstract available


  172. WANG Q, Cai WZ, Wang QR, Zhu MQ, et al
    Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia.
    Am J Hematol. 2022 Oct 11. doi: 10.1002/ajh.26758.
    PubMed     Abstract available


  173. KITTAI AS, Huang Y, Beckwith KA, Bhat SA, et al
    Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Am J Hematol. 2022 Oct 10. doi: 10.1002/ajh.26755.
    PubMed     Abstract available


  174. LANZA L, Koroveshi B, Barducchi F, Lorenzo A, et al
    A new diagnosis of monoclonal B-cell lymphocytosis with cytoplasmic inclusions in a patient with COVID-19.
    Am J Hematol. 2022;97:1372-1373.
    PubMed    



  175. Abstracts from the 2022 Lymphoma, Leukemia and Myeloma Congress October 18-22, 2022.
    Am J Hematol. 2022;97 Suppl 3:S3-S40.
    PubMed    


    September 2022
  176. RADKIEWICZ C, Bruchfeld JB, Weibull CE, Jeppesen ML, et al
    Sex differences in lymphoma incidence and mortality by subtype: a population-based study.
    Am J Hematol. 2022 Sep 30. doi: 10.1002/ajh.26744.
    PubMed     Abstract available


  177. RIVERA D, Kim K, Kanagal-Shamanna R, Borthakur G, et al
    Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes.
    Am J Hematol. 2022 Sep 18. doi: 10.1002/ajh.26731.
    PubMed     Abstract available


  178. ZIPPER R, Fong V, Toker M, Reddy N, et al
    Neutrophilic Eccrine Hidradenitis in a pediatric patient with Acute Myeloid Leukemia.
    Am J Hematol. 2022 Sep 16. doi: 10.1002/ajh.26733.
    PubMed    


  179. WRIGHT MF, Pozdnyakova O, Hasserjian RP, Aggarwal N, et al
    Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1.
    Am J Hematol. 2022 Sep 15. doi: 10.1002/ajh.26730.
    PubMed    


  180. VENUGOPAL S, DiNardo CD, Loghavi S, Qiao W, et al
    Differential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia.
    Am J Hematol. 2022 Sep 10. doi: 10.1002/ajh.26724.
    PubMed     Abstract available


  181. LEE BJ, Griffin SP, Doh J, Chan A, et al
    CD19-Directed Immunotherapy Use in KMT2A-Rearranged Acute Leukemia: A Case Report and Literature Review of Increased Lymphoid to Myeloid Lineage Switch.
    Am J Hematol. 2022 Sep 3. doi: 10.1002/ajh.26713.
    PubMed    


  182. FALINI B
    Acute myeloid leukemia risk models: Where do we stand?
    Am J Hematol. 2022;97:1124-1126.
    PubMed    


    August 2022
  183. PRATZ KW, DiNardo CD, Selleslag D, Li J, et al
    Postremission cytopenia management in patients with AML treated with venetoclax and azacitidine in VIALE-A.
    Am J Hematol. 2022 Aug 30. doi: 10.1002/ajh.26692.
    PubMed    


  184. JONAS BA, DiNardo C, Fracchiolla N, Pristupa A, et al
    Use of CYP3Ai and impact on outcomes in patients with AML treated with venetoclax plus azacitidine in the VIALE-A study.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26707.
    PubMed    


  185. BORTHAKUR G, Ravandi F, Patel K, Wang X, et al
    Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD And
    Am J Hematol. 2022 Aug 26. doi: 10.1002/ajh.26700.
    PubMed     Abstract available


  186. SHORT NJ, Macaron W, Kadia T, Dinardo C, et al
    Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience MRD recurrence following MRD-negative remission.
    Am J Hematol. 2022 Aug 24. doi: 10.1002/ajh.26698.
    PubMed    


  187. TEFFERI A, Begna KH, McCullough KB
    Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day).
    Am J Hematol. 2022 Aug 22. doi: 10.1002/ajh.26695.
    PubMed    


  188. LACHOWIEZ CA, Reville PK, Kantarjian H, Jabbour E, et al
    Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
    Am J Hematol. 2022 Aug 22. doi: 10.1002/ajh.26694.
    PubMed     Abstract available


  189. JABBOUR E, Sasaki K, Haddad FG, Issa GC, et al
    Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
    Am J Hematol. 2022 Aug 13. doi: 10.1002/ajh.26689.
    PubMed     Abstract available


  190. KANTARJIAN HM, Jabbour E, Deininger M, Abruzzese E, et al
    Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
    Am J Hematol. 2022 Aug 12. doi: 10.1002/ajh.26686.
    PubMed     Abstract available


  191. SHAH MV, Chhetri R, Dholakia R, Kok CH, et al
    Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
    Am J Hematol. 2022;97:1013-1022.
    PubMed     Abstract available


    July 2022
  192. SHORT NJ, Kantarjian H
    Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Past Discoveries and Future Directions.
    Am J Hematol. 2022 Jul 24. doi: 10.1002/ajh.26667.
    PubMed     Abstract available


  193. HERRMANN L, Bischof L, Backhaus D, Brauer D, et al
    Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2022 Jul 8. doi: 10.1002/ajh.26653.
    PubMed    


  194. PETER B, Eisenwort G, Sadovnik I, Bauer K, et al
    BRD4 Degradation Blocks Expression of MYC and Multiple Forms of Stem Cell Resistance in Ph(+) Chronic Myeloid Leukemia.
    Am J Hematol. 2022 Jul 6. doi: 10.1002/ajh.26650.
    PubMed     Abstract available


  195. BADAR T, Atallah E, Shallis RM, Goldberg AD, et al
    Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
    Am J Hematol. 2022;97:E232-E235.
    PubMed    


    June 2022
  196. ALCAZER V, Bonaventura P, Tonon L, Michel E, et al
    HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy.
    Am J Hematol. 2022 Jun 27. doi: 10.1002/ajh.26647.
    PubMed     Abstract available


  197. NICHOLS ED, Jammal N, Chew S, Bryan J, et al
    Real-life incidence of thrombotic events in leukemia patients treated with ponatinib.
    Am J Hematol. 2022 Jun 27. doi: 10.1002/ajh.26645.
    PubMed    


  198. JABBOUR E, Kantarjian H
    Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy and Monitoring.
    Am J Hematol. 2022 Jun 25. doi: 10.1002/ajh.26642.
    PubMed     Abstract available


  199. DHOPESHWARKAR N, Yang W, Hennessy S, Rhodes JM, et al
    Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26632.
    PubMed    


  200. JABBOUR EJ, Short NJ, Jain N, Jammal N, et al
    Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10(-4) and Higher.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
    PubMed     Abstract available


  201. TEFFERI A, Gangat N, Al-Kali A, Alkhateeb H, et al
    A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
    Am J Hematol. 2022 Jun 15. doi: 10.1002/ajh.26630.
    PubMed     Abstract available


  202. BARON F, Labopin M, Tischer J, Ciceri F, et al
    Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients >/=55 years of age.
    Am J Hematol. 2022 Jun 13. doi: 10.1002/ajh.26627.
    PubMed     Abstract available


    May 2022
  203. PAUL S, Kantarjian H, Sasaki K, Marx K, et al
    Intrathecal Prophylaxis with 12 Versus 8 Administrations Reduces the Incidence of Central Nervous System Relapse in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 28. doi: 10.1002/ajh.26622.
    PubMed    


  204. BEELEN DW, Stelljes M, Remenyi P, Wagner-Drouet EM, et al
    Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26620.
    PubMed     Abstract available


  205. VABRE C, Zelmat Y, Gauthier M, Pajiep M, et al
    Incident users of tyrosine kinase inhibitors in chronic myeloid leukemia patients: analysis of anticancer treatment trajectories - A French population-based study using the French national health data system.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26621.
    PubMed    


  206. GAMBACORTI-PASSERINI C, Nicolini FE, Larson RA, Aroldi A, et al
    Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
    Am J Hematol. 2022 May 23. doi: 10.1002/ajh.26618.
    PubMed    


  207. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2022 May 18. doi: 10.1002/ajh.26601.
    PubMed     Abstract available


  208. JONAS BA, Wei AH, Recher C, DiNardo CD, et al
    Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26600.
    PubMed    


  209. CHERNG HJ, Khwaja R, Kanagal-Shamanna R, Tang G, et al
    TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26595.
    PubMed     Abstract available


  210. GOTTLIEB DJ, Sutrave G, Jiang W, Avdic S, et al
    Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant.
    Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26594.
    PubMed     Abstract available


  211. SINGH A, Al-Kali A, Begna KH, Litzow MR, et al
    Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Am J Hematol. 2022;97:630-637.
    PubMed     Abstract available


  212. WANG J, Zhang X, Zhou Z, Liu Y, et al
    A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
    PubMed     Abstract available


  213. GORDON MJ, Ferrajoli A
    Unusual complications in the management of chronic lymphocytic leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26585.
    PubMed     Abstract available


    April 2022
  214. PEREZ-CARRETERO C, Hernandez-Sanchez M, Gonzalez T, Quijada-Alamo M, et al
    TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26578.
    PubMed     Abstract available


  215. KIM K, Konopleva M, DiNardo CD, Borthakur G, et al
    Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
    Am J Hematol. 2022 Apr 12. doi: 10.1002/ajh.26572.
    PubMed     Abstract available


  216. TANG B, Lee JB, Cheng S, Pan T, et al
    Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study.
    Am J Hematol. 2022 Apr 6. doi: 10.1002/ajh.26564.
    PubMed    


  217. SASAKI K, Ravandi F, Kadia T, DiNardo C, et al
    Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26557.
    PubMed     Abstract available


  218. INZOLI E, Aroldi A, Piazza R, Gambacorti-Passerini C, et al
    Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26556.
    PubMed     Abstract available


  219. LARSSON K, Soderling J, Hoglund M, Glimelius I, et al
    Cardiovascular disease in patients with chronic lymphocytic leukemia. A Swedish nationwide register study with matched comparators.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26558.
    PubMed    


  220. MCLAUGHLIN N, Ruan G, Day CN, Harmsen WS, et al
    A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004-2015.
    Am J Hematol. 2022;97:E144-E147.
    PubMed    


    March 2022
  221. HADDAD FG, Sasaki K, Issa GC, Garcia-Manero G, et al
    Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors.
    Am J Hematol. 2022 Mar 31. doi: 10.1002/ajh.26550.
    PubMed     Abstract available


  222. COOK L, Al-Yousuf H, Mohamedbhai S, Bain BJ, et al
    Hyposplenism in adult T-cell leukemia/lymphoma.
    Am J Hematol. 2022 Mar 26. doi: 10.1002/ajh.26547.
    PubMed    


  223. TORELLI GF, Chiaretti S, Peragine N, Barberi W, et al
    Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.
    Am J Hematol. 2022 Mar 22. doi: 10.1002/ajh.26537.
    PubMed    


  224. KRAKOW EF, Walter RB, Nathe JM, Perez T, et al
    Intensive Chemotherapy for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation.
    Am J Hematol. 2022 Mar 18. doi: 10.1002/ajh.26540.
    PubMed    


  225. SMITH AC, Maze D, Xia D, Capo-Chichi JM, et al
    A t(6;14;9)(p22;q22;q34) Three-Way Translocation: Description of a Cytogenetically Visible Variant t(6;9) in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Mar 16. doi: 10.1002/ajh.26534.
    PubMed    


  226. GALLANT RE, Arroyo K, Bracci PM, Li S, et al
    Clinical characteristics of cytomegalovirus-positive pediatric acute lymphoblastic leukemia at diagnosis.
    Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26528.
    PubMed    


  227. SHORT NJ, Macaron W, Konopleva M, Ravandi F, et al
    Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
    Am J Hematol. 2022 Mar 10. doi: 10.1002/ajh.26526.
    PubMed    


  228. KENNEDY VE, Hui G, Azenkot T, Gaut D, et al
    Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Mar 9. doi: 10.1002/ajh.26524.
    PubMed    


  229. ORTIZ-MALDONADO V, Alonso-Saladrigues A, Espanol-Rego M, Martinez-Cibrian N, et al
    Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
    Am J Hematol. 2022 Mar 7. doi: 10.1002/ajh.26519.
    PubMed     Abstract available


    February 2022
  230. MOSHREF RAZAVI H, Yu R
    Myeloid neoplasm with PDGFRB rearrangement, presenting as systemic mastocytosis-chronic eosinophilic leukemia.
    Am J Hematol. 2022 Feb 21. doi: 10.1002/ajh.26505.
    PubMed    


  231. POMMERT L, Schafer ES, Malvar J, Gossai N, et al
    Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26510.
    PubMed     Abstract available


  232. ARBER DA, Hasserjian RP, Orazi A, Mathews V, et al
    Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26503.
    PubMed    


  233. BALL S, Jain AG, Aguirre LE, Al Ali N, et al
    Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26504.
    PubMed    


  234. SHI M, Li L, Wang S, Cheng H, et al
    Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26506.
    PubMed     Abstract available


  235. MOLICA S, Giannarelli D, Visentin A, Reda G, et al
    Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
    Am J Hematol. 2022 Feb 16. doi: 10.1002/ajh.26502.
    PubMed    


  236. SENAPATI J, Shoukier M, Garcia-Manero G, Wang X, et al
    Activity of Decitabine as Maintenance Therapy in Core Binding Factor Acute Myeloid Leukemia.
    Am J Hematol. 2022 Feb 12. doi: 10.1002/ajh.26496.
    PubMed     Abstract available


  237. POURHASSAN H, Yang D, Afkhami M, Pillai R, et al
    High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.
    Am J Hematol. 2022 Feb 7. doi: 10.1002/ajh.26490.
    PubMed    


  238. RACK K, De Bie J, Ameye G, Gielen O, et al
    Optimizing the Diagnostic Workflow for Acute Lymphoblastic Leukemia by Optical Genome Mapping.
    Am J Hematol. 2022 Feb 4. doi: 10.1002/ajh.26487.
    PubMed     Abstract available


  239. ALLSUP DJ, Craig Z, Cairns D, Howard D, et al
    Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
    Am J Hematol. 2022 Feb 2. doi: 10.1002/ajh.26483.
    PubMed    


  240. UJJANI C, Greninger AL, Shadman M, Hill JA, et al
    Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Am J Hematol. 2022;97:E67-E69.
    PubMed    


  241. GAO F, Gao Y, Luo Y, Yu J, et al
    Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transpl
    Am J Hematol. 2022;97:E44-E47.
    PubMed    


  242. KUNO M, Yamasaki S, Fujii N, Ishida Y, et al
    Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation.
    Am J Hematol. 2022;97:185-193.
    PubMed     Abstract available


    January 2022
  243. SZUBER N, Elliott M, Tefferi A
    Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.
    Am J Hematol. 2022 Jan 28. doi: 10.1002/ajh.26481.
    PubMed     Abstract available


  244. LAZARIAN G, Theves F, Hormi M, Letestu R, et al
    TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.
    Am J Hematol. 2022 Jan 26. doi: 10.1002/ajh.26479.
    PubMed    


  245. IJURKO C, Gonzalez-Garcia N, Galindo-Villardon P, Hernandez-Hernandez A, et al
    A 29-gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival.
    Am J Hematol. 2022 Jan 24. doi: 10.1002/ajh.26477.
    PubMed     Abstract available


  246. DORFMAN DM, Pinkus GS
    A case of peripheral T-cell lymphoma, NOS mimicking acute monocytic leukemia.
    Am J Hematol. 2022 Jan 22. doi: 10.1002/ajh.26476.
    PubMed    


  247. ROSSI M, Nizzoli ME, Galli A, Roncoroni E, et al
    Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome.
    Am J Hematol. 2022 Jan 18. doi: 10.1002/ajh.26469.
    PubMed    


  248. DAHLEN T, Edgren G, Ljungman P, Flygt H, et al
    Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
    Am J Hematol. 2022 Jan 11. doi: 10.1002/ajh.26463.
    PubMed     Abstract available


  249. JELLOUL FZ, Yang R, Wang P, Garces S, et al
    Non-Coding NOTCH1 Mutations in Chronic Lymphocytic Leukemia Negatively Impact Prognosis.
    Am J Hematol. 2022 Jan 6. doi: 10.1002/ajh.26457.
    PubMed    


  250. PATNAIK MM, Tefferi A
    Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.
    Am J Hematol. 2022 Jan 5. doi: 10.1002/ajh.26455.
    PubMed     Abstract available


  251. REVILLE PK, Sasaki K, Kantarjian HM, Daver NG, et al
    Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26451.
    PubMed     Abstract available


  252. NUMAN Y, Abdel Rahman Z, Grenet J, Boisclair S, et al
    Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26447.
    PubMed     Abstract available


  253. NAGLER A, Labopin M, Craddock C, Socie G, et al
    Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26442.
    PubMed     Abstract available


  254. RIBEIL JA
    Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?
    Am J Hematol. 2022;97:4-6.
    PubMed    


    December 2021
  255. DAVIDS MS, Shadman M, Parikh SA, Ujjani C, et al
    A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.
    Am J Hematol. 2021 Dec 20. doi: 10.1002/ajh.26444.
    PubMed    


  256. VISENTIN A, Mauro FR, Cibien F, Vitale C, et al
    Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
    Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26437.
    PubMed    


  257. SEGOT A, Stalder G, de Leval L, Solly F, et al
    Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.
    Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26436.
    PubMed    


  258. FORTES BH, Dalvin LA, Hogan WJ, Patnaik MM, et al
    Isolated T-cell acute lymphoblastic leukemic optic disc infiltration.
    Am J Hematol. 2021;96:1717-1718.
    PubMed    


    November 2021
  259. SANTOS FM, Ghelfond G, Seguro FS, Abdo ANR, et al
    Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia.
    Am J Hematol. 2021 Nov 25. doi: 10.1002/ajh.26424.
    PubMed    


  260. POPOVIC R, Dunbar F, Lu C, Robinson K, et al
    Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
    Am J Hematol. 2021 Nov 14. doi: 10.1002/ajh.26411.
    PubMed    


  261. CHO BS, Min GJ, Park SS, Yoon SY, et al
    Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
    Am J Hematol. 2021;96:1441-1449.
    PubMed     Abstract available


    October 2021
  262. SASAKI K, Kadia T, Begna K, DiNardo CD, et al
    Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.
    Am J Hematol. 2021 Oct 30. doi: 10.1002/ajh.26395.
    PubMed     Abstract available


  263. TROUSSARD X, Maitre E, Cornet E
    Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26390.
    PubMed     Abstract available


  264. MUCHTAR E, Koehler AB, Johnson MJ, Rabe KG, et al
    Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Am J Hematol. 2021 Oct 26. doi: 10.1002/ajh.26388.
    PubMed     Abstract available


  265. ZHANG Y, Li X, Weng X, Shen Y, et al
    Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: a single-arm, phase 2 trial (RJ-AML 2014).
    Am J Hematol. 2021 Oct 23. doi: 10.1002/ajh.26386.
    PubMed     Abstract available


  266. HALLEK M, Al-Sawaf O
    Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26367.
    PubMed     Abstract available


  267. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
    BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Am J Hematol. 2021;96:1195-1203.
    PubMed     Abstract available


  268. GRIMM J, Jentzsch M, Bill M, Backhaus D, et al
    Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:1287-1294.
    PubMed     Abstract available


    September 2021
  269. FURSTENAU M, Giza A, Stumpf T, Robrecht S, et al
    Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
    Am J Hematol. 2021 Sep 30. doi: 10.1002/ajh.26363.
    PubMed    


    August 2021
  270. SALIBA AN, Litzow MR, Gangat N, Al-Kali A, et al
    Outcomes of Venetoclax-Based Therapy in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2021 Aug 24. doi: 10.1002/ajh.26334.
    PubMed    


  271. ZHOU B, Chu X, Tian H, Liu T, et al
    The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-year Retrospective Study.
    Am J Hematol. 2021 Aug 18. doi: 10.1002/ajh.26324.
    PubMed     Abstract available


  272. ZHANG M, Xiao H, Shi J, Tan Y, et al
    Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: a phase III randomized controlled study.
    Am J Hematol. 2021 Aug 9. doi: 10.1002/ajh.26317.
    PubMed     Abstract available


  273. ALWASH Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, et al
    Development of TP53 Mutations Over the Course of Therapy for Acute Myeloid Leukemia.
    Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.
    PubMed     Abstract available


  274. CHEN Z, Song J, Wang W, Bai J, et al
    A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia.
    Am J Hematol. 2021 Aug 2. doi: 10.1002/ajh.26309.
    PubMed     Abstract available


    July 2021
  275. VARETTONI M, Orlandi E, Zibellini S, Rossi M, et al
    Prognostic impact of somatic mutations on time to first treatment: results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
    Am J Hematol. 2021 Jul 30. doi: 10.1002/ajh.26302.
    PubMed    


  276. KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
    Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
    Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.
    PubMed    


  277. BROCCOLI A, Argnani L, Nanni L, Terragna C, et al
    The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a thirty-year experience.
    Am J Hematol. 2021 Jul 10. doi: 10.1002/ajh.26287.
    PubMed     Abstract available


  278. GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
    Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Am J Hematol. 2021;96:781-789.
    PubMed     Abstract available


  279. HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
    Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
    Am J Hematol. 2021;96:E259-E262.
    PubMed    


  280. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:E237-E239.
    PubMed    


  281. JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
    A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
    Am J Hematol. 2021;96:E226-E229.
    PubMed    


  282. OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
    Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
    Am J Hematol. 2021;96:E223-E225.
    PubMed    


    June 2021
  283. JABBOUR E, Patel K, Jain N, Duose D, et al
    Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
    Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
    PubMed     Abstract available


  284. LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
    Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
    PubMed    


  285. MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
    Ruxolitinib for refractory large granular lymphocyte leukemia.
    Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.
    PubMed    


  286. HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
    Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
    Am J Hematol. 2021;96:E187-E189.
    PubMed    


    May 2021
  287. AL-SAWAF O, Gentile B, Devine J, Zhang C, et al
    Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26260.
    PubMed     Abstract available


  288. PICIOCCHI A, Messina M, Elia L, Vitale A, et al
    Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.
    Am J Hematol. 2021 May 28. doi: 10.1002/ajh.26253.
    PubMed    


  289. ST MARTIN EC, Ferrer A, Wudhikarn K, Mangaonkar A, et al
    Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes.
    Am J Hematol. 2021 May 24. doi: 10.1002/ajh.26250.
    PubMed    


  290. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
    PubMed    


  291. JAIN N, Maiti A, Ravandi F, Konopleva M, et al
    Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia.
    Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.
    PubMed     Abstract available


  292. MORABITO F, Del Poeta G, Mauro FR, Reda G, et al
    TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
    Am J Hematol. 2021 May 14. doi: 10.1002/ajh.26235.
    PubMed    


  293. HALL KH, Brooks A, Waller EK
    Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26231.
    PubMed    


  294. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Am J Hematol. 2021;96:E168-E171.
    PubMed    


  295. OTHMAN TA, Mei M, Zhang J, Aldoss I, et al
    Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Am J Hematol. 2021;96:E140-E143.
    PubMed    


    April 2021
  296. KADIA TM, Ravandi F, Borthakur G, Konopleva M, et al
    Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2021 Apr 26. doi: 10.1002/ajh.26206.
    PubMed     Abstract available


  297. YILMAZ M, Daver N, Borthakur G, Kadia T, et al
    FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
    Am J Hematol. 2021 Apr 23. doi: 10.1002/ajh.26202.
    PubMed    


  298. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
    Am J Hematol. 2021 Apr 20. doi: 10.1002/ajh.26201.
    PubMed    


  299. JAMY O, Godby R, Sarmad R, Costa LJ, et al
    Survival of Chronic Myeloid Leukemia Patients in Comparison to the General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26195.
    PubMed    


  300. PELLAND-MARCOTTE MC, Kulkarni K, Athale UH, Pole JD, et al
    Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C.
    Am J Hematol. 2021 Apr 13. doi: 10.1002/ajh.26193.
    PubMed     Abstract available


  301. APEL A, Moshe Y, Ofran Y, Gural A, et al
    Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice.
    Am J Hematol. 2021 Apr 9. doi: 10.1002/ajh.26190.
    PubMed     Abstract available


  302. DONG N, Castillo Tokumori F, Isenalumhe L, Zhang Y, et al
    Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases.
    Am J Hematol. 2021 Apr 5. doi: 10.1002/ajh.26183.
    PubMed     Abstract available


  303. GANGAT N, Szuber N, Jawaid T, Hanson CA, et al
    Young platelet millionaires with essential thrombocythemia.
    Am J Hematol. 2021;96:E93-E95.
    PubMed    


  304. PARDANANI A
    Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:508-525.
    PubMed     Abstract available


    April 2020
  305. OHANIAN M, Telouk P, Kornblau S, Albarede F, et al
    A heavy metal baseline score predicts outcome in acute myeloid leukemia.
    Am J Hematol. 2020;95:422-434.
    PubMed     Abstract available


  306. COLTRO G, Antelo G, Lasho TL, Finke CM, et al
    Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Am J Hematol. 2020;95:E86-E89.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.